Literature DB >> 2570132

Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing presenile familial and sporadic senile cases.

P Herregodts1, M Bruyland, J De Keyser, C Solheid, Y Michotte, G Ebinger.   

Abstract

Norepinephrine, epinephrine, dopamine, serotonin and their major metabolites were measured in 20 regions of the left hemisphere in 4 presenile familial cases of Alzheimer-type dementia and 4 sporadic senile cases. Both groups were compared to values in normal brains obtained in our laboratory. Quantitative determination of the monoamines was performed by HPLC with electrochemical detection. The clinical diagnosis of Alzheimer-type dementia was confirmed by histological examination of the right hemisphere and brain stem. The serotonergic system was dramatically affected in the familial cases with very low or undetectable serotonin concentrations in most cortical and subcortical areas studied and an important cell loss in the nucleus raphe dorsalis, origin of the main ascending serotonergic system. In the senile demented patients the serotonergic deficit is less important but still clearly present. The noradrenergic, adrenergic and dopaminergic systems were less affected by the disease process in senile sporadic as well as in the presenile familial type of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570132     DOI: 10.1016/0022-510x(89)90179-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 2.  Is ammonia a pathogenetic factor in Alzheimer's disease?

Authors:  N Seiler
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

3.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Noradrenergic dysfunction in Alzheimer's disease.

Authors:  Mary Gannon; Pulin Che; Yunjia Chen; Kai Jiao; Erik D Roberson; Qin Wang
Journal:  Front Neurosci       Date:  2015-06-17       Impact factor: 4.677

5.  The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

Authors:  Yannick Vermeiren; Debby Van Dam; Tony Aerts; Sebastiaan Engelborghs; Jean-Jacques Martin; Peter P De Deyn
Journal:  Alzheimers Res Ther       Date:  2015-02-11       Impact factor: 6.982

Review 6.  Noradrenergic Hypothesis Linking Neurodegeneration-Based Cognitive Decline and Astroglia.

Authors:  Giampiero Leanza; Rosario Gulino; Robert Zorec
Journal:  Front Mol Neurosci       Date:  2018-07-27       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.